Update regarding Closing of the first stage of the Binding agreement of investment in and acquisition of IOPtima

Tel Aviv (February 11, 2018) – Further to BioLight’s announcement dated November 31, 2017 regarding signing a binding agreement for the investment in and the acquisition in stages of its subsidiary IOPtima (the “Agreement”) by the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co. (“the Acquirer”), and in accordance with …

Continue reading

DiagnosTear Ltd. – Recruitment of the first participant for clinical trial using the TeaRx ™ technology

The Company hereby announces that on August 31, 2017, DiagnosTear Ltd. (“DiagnosTear”) announced the recruitment of a first participant for an additional clinical trial to examine a product based on the TeaRx ™ technology, which is used to diagnose, personalize treatment and monitoring Dry eye syndrome by examining the composition …

Continue reading

Successful Feasibility Clinical Study Results for the Detection of Prostate Cancer with CellDetect Non-Invasive Test

BioLight announced on promising results from a feasibility clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect® technology. The study successfully demonstrated the feasibility of detecting intact cells originating in the prostate from urine samples following prostate massage.

Link to complete article

Continue reading